These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32296740)

  • 21. Galactorrhea and hyperprolactinemia.
    Sakiyama R; Quan M
    Obstet Gynecol Surv; 1983 Dec; 38(12):689-700. PubMed ID: 6361641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Excessively high prolactin level in a patient with a nonprolactin-secreting adenoma. Case report.
    Albuquerque FC; Hinton DR; Weiss MH
    J Neurosurg; 1998 Dec; 89(6):1043-6. PubMed ID: 9833836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Galactorrhea].
    Iino Y; Mori H
    Nihon Rinsho; 1997 Nov; 55(11):2914-9. PubMed ID: 9396287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simulation of a prolactin-secreting adenoma by an intrasellar craniopharyngioma.
    Gamblin GT; James LP; Thomas J; Six E; Eil C
    Neurosurgery; 1985 May; 16(5):689-92. PubMed ID: 4039804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
    Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
    J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idiopathic Hyperprolactinemia Presenting as Polycystic Ovary Syndrome in Identical Twin Sisters: A Case Report and Literature Review.
    Goyal A; Ganie MA
    Cureus; 2018 Jul; 10(7):e3004. PubMed ID: 30250766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Heterogeneity of immunoreactive prolactin in hyperprolactinemia of various origin].
    Bulatov AA; Makarovskaia EE; Dzeranova LK; Smirnova NB; Chernogolov VA; Marova EI; Mel'nichenko GA; Dedov II
    Probl Endokrinol (Mosk); 1992; 38(6):13-6. PubMed ID: 1302839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
    Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Khandji AG; Post KD
    Pituitary; 2004; 7(1):21-30. PubMed ID: 15638294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
    Cavallaro R; Cocchi F; Angelone SM; Lattuada E; Smeraldi E
    J Clin Psychiatry; 2004 Feb; 65(2):187-90. PubMed ID: 15003071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients.
    Lu CC; Hsieh CJ
    Kaohsiung J Med Sci; 2012 Feb; 28(2):94-9. PubMed ID: 22313536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.
    Cohen LG; Biederman J
    J Child Adolesc Psychopharmacol; 2001; 11(4):435-40. PubMed ID: 11838826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation.
    Levine SN; Ishaq S; Nanda A; Wilson JD; Gonzalez-Toledo E
    Ann Diagn Pathol; 2013 Aug; 17(4):361-6. PubMed ID: 23602507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary Hypothyroidism with Exceptionally High Prolactin-A Really Big Deal.
    Khorassanizadeh R; Sundaresh V; Levine SN
    World Neurosurg; 2016 Jul; 91():675.e11-4. PubMed ID: 27155380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idiopathic hyperprolactinemia in a 15-year-old boy: a case report and literature review.
    Jaruratanasirikul S; Janejindamai S
    J Med Assoc Thai; 1995 Jul; 78(7):388-92. PubMed ID: 7658185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
    Tollin SR
    J Endocrinol Invest; 2000 Dec; 23(11):765-70. PubMed ID: 11194712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperprolactinemia: etiology, diagnosis, and management.
    Mah PM; Webster J
    Semin Reprod Med; 2002 Nov; 20(4):365-74. PubMed ID: 12536359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ectopic hyperprolactinaemia in a woman with a mesocolic perivascular epithelioid cell tumor ("PEComa").
    Proust-Lemoine E; Mitchell V; Deruelle P; Lamblin A; Néraud B; Leroy X; Leteurtre E; Dewailly D
    Ann Endocrinol (Paris); 2008 Jun; 69(3):240-3. PubMed ID: 18395182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient?
    Philipse E; Philipse E; Twickler T; Van Craenenbroeck A; Couttenye MM; Van Gaal L
    Case Rep Nephrol; 2017; 2017():3729629. PubMed ID: 28791188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.